Focus: R-Pharm US is a specialty biotech focused on acquiring and commercializing small-molecule products across cardiovascular, neurology, infectious diseases, oncology, and respiratory indications. The company operates from Princeton, NJ and generates significant revenue from a concentrated portfolio of established drugs.
Profile data last refreshed 5h ago · AI intelligence enriched 1w ago
No open roles listed right now. Follow R-Pharm US to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from R-Pharm US's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for R-Pharm US
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Flagship product generating 37% of company revenue; patent expiration in August 2026 represents imminent and material revenue cliff.
Second-largest revenue contributor; already post-LOE with no defined expiration date suggests established generic competition and stable cash generation.
Patent expiration in March 2028; approaching loss-of-exclusivity represents significant revenue cliff within 2–3 years.
Post-LOE generic product; stable revenue contribution in ophthalmology segment.
Patent expiration in June 2029; third-largest cliff in near-term patent schedule, representing $33M revenue at risk.
Longest patent protection window (LOE August 2037); contributes to stable mid-term revenue with low near-term erosion risk.
Combination hypertension product; patent protection until July 2031 provides stable mid-term revenue with acceptable erosion timeline.
Longest patent window in portfolio (LOE September 2039); niche indication in emergency diabetes management with stable long-term revenue.
Post-LOE generic diuretic; modest revenue contribution in mature hypertension market with low growth potential.
615 discontinued, 173 duplicate formulations not shown
+18 more products with revenue data
No open positions listed yet. Check their careers page directly.
Source: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via Big Local News
+116 more products
Recent large-scale layoff, zero active hiring, and approaching patent cliffs on flagship product create high organizational volatility risk; job security is compromised.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo